Diagnosis & Testing

Diagnostic Criteria

ADPKD diagnosis relies primarily on imaging studies combined with family history. For patients with a positive family history, age-specific cyst count criteria are applied — bilateral kidneys must show multiple cysts as defined by the Pei-Ravine or KDIGO 2025 criteria. For those without a family history, more cysts are required and other causes of bilateral cystic kidney disease must be excluded.

• Imaging (ultrasound, CT, or MRI): Age-specific thresholds for cyst count; cysts must be bilateral. The 2025 KDIGO guideline provides updated criteria accounting for typical vs. atypical imaging patterns.
• Family history: A first-degree relative with ADPKD significantly lowers the imaging threshold for diagnosis.
• Genetic testing: Used when imaging is equivocal, family history is absent, or for reproductive planning.

Key Indicators

ADPKD patients need to monitor many more indicators than those listed below. In addition to traditional kidney function and imaging markers, cystatin C, electrolytes, parathyroid hormone (PTH), iron metabolism, liver function, coagulation, lipids, and urinary albumin all matter at different disease stages.

eGFR (Estimated Glomerular Filtration Rate)

The core indicator for assessing kidney function. Normal value is ≥ 90 mL/min/1.73m². In early ADPKD, eGFR may remain normal for years before gradually declining. Recheck every 3–6 months as recommended by your doctor. Multiple equations exist for calculating eGFR (the 2021 CKD-EPI creatinine equation, cystatin C equation, and combined creatinine–cystatin C equation). For the meaning of each parameter and applicable boundaries, see eGFR detailed explanation.

TKV (Total Kidney Volume)

Measured by MRI or ultrasound, TKV is a key indicator for assessing cyst burden and disease progression rate. Rapid TKV growth indicates high risk and is a core parameter in the Mayo Imaging Classification and RAAP risk stratification. Typically measured annually. Note: it is the rate of TKV growth and classification category — not absolute volume alone — that matters for risk assessment.

Serum Creatinine

A traditional kidney function marker used to calculate eGFR. It is affected by muscle mass, age, and sex, so it is less accurate than eGFR when interpreted alone. For measurement methods (Jaffe vs. enzymatic), influencing factors, and safety guidance for acute elevations, see serum creatinine detailed explanation.

UPCR (Urine Protein-to-Creatinine Ratio)

Assesses urinary protein excretion. Normal is < 150 mg/g; ADPKD patients should aim to keep UPCR below 500. Proteinuria is a marker of disease progression and an important target for blood pressure management with ACE inhibitors or ARBs.

Blood Pressure

Target blood pressure for ADPKD patients is < 130/80 mmHg. Home measurement and trend recording are recommended — bring your records to appointments for your doctor's reference.

Genetic Testing

Genetic testing can identify mutations in PKD1 (accounting for ~78% of cases) or PKD2 (~15%). It is particularly valuable when family history is unclear, imaging is atypical, or for reproductive planning. Approximately 10% of patients have no identifiable mutation in known genes, which may involve other genes (e.g., GANAB, DNAJB11) or complex variants.

• When indicated: equivocal imaging, no family history, atypical presentation, reproductive planning, or when results may change management (e.g., tolvaptan eligibility).
• Counseling needed: Results should be interpreted with a genetic counselor. Findings may affect reproductive decisions and family communication.

Risk Stratification

Risk stratification helps predict how quickly ADPKD may progress and guides treatment intensity. Two main tools are used:

• Mayo Imaging Classification: Based on height-adjusted TKV and age, patients are classified into typical (1A–1E) or atypical categories. Higher classes (1C–1E) indicate faster progression.
• RAAP (Risk of ADPKD Progression): Combines TKV, age, and genotype (PKD1 truncating vs. non-truncating vs. PKD2) to classify patients as low, intermediate, or high risk — helping clinicians decide whether to initiate disease-modifying therapy such as tolvaptan.
• Rapid progression definition: Generally defined as eGFR decline exceeding expected age-related loss, or TKV growth rate placing the patient in a high-risk Mayo class. Early identification enables timely intervention.

Monitoring Frequency by Stage

Monitoring intensity should adapt to disease stage and risk profile. The following is a general framework — your nephrologist will personalize the schedule:

• CKD Stage 1–2 (eGFR ≥ 60): eGFR every 6–12 months; blood pressure every 3–6 months (home monitoring encouraged); TKV annually for risk stratification; UPCR annually or with symptoms.
• CKD Stage 3a–3b (eGFR 30–59): eGFR every 3–6 months; blood pressure every 3 months; TKV annually if rapid progression suspected; UPCR every 6–12 months; monitor electrolytes, PTH, and hemoglobin.
• CKD Stage 4 (eGFR 15–29): eGFR every 2–3 months; blood pressure every 3 months; add electrolytes, acid–base, hemoglobin, iron studies, PTH every 3–6 months; prepare for kidney replacement therapy planning.
• CKD Stage 5 (eGFR < 15): eGFR every 1–2 months; comprehensive metabolic and hematologic panel every 1–3 months; coordinate with transplant/dialysis team.

← Back to Knowledge Base